While exogenous insulin therapy is still the central intervention to treat T1D, a more complete understanding of T1D as a heterogeneous disease with multiple affected immunologic and metabolic pathways encourages versatile modalities to treat, delay and even prevent T1D. The gene discussed is INS; the disease is type 1 diabetes mellitus.